OGESTREL 0.5/50 Rx
Generic Name and Formulations:
Norgestrel 0.5mg, ethinyl estradiol 50micrograms (21 tabs); inert (7 tabs).
Indications for OGESTREL 0.5/50:
1 tab daily for 28 days; repeat.
Progestin + estrogen.
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).
Smokers over 35 years of age: not recommended. Uncontrolled hypertension. Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Nursing mothers: not recommended.
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels.
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.
- Necessary Procedure Leads to Assault and Battery Charges
- Certain Antibiotics May Up Diabetes Risk
- FDA: Life-Threatening Interaction Possible Between Antivirals, Amiodarone
- Study: Pregnant, Breastfeeding Women Not Consuming Enough of This Nutrient
- Study: Abuse, Addiction, Poisoning Diagnoses Decrease with Reformulated Oxycontin
- Three-Month Paliperidone Palmitate to Delay Relapse in Schizophrenia: Phase 3 Data Published
- Diabetes May Predispose to More Advanced Breast Cancer
- Treatment, Disease Management Helping Dialysis Patients Live Longer
- More Nephrologists Reporting Pregnant Patients on Dialysis
- Public Health Emergency Declared in IN Following HIV Outbreak